U.S. medical device company Accuray Inc. (NASDAQ: ARAY) has announced that it has received market approval from Chinese regulatory authorities for its Accuray Precision Treatment Planning System (TPS). This approval will enable the integration of the TPS with the Tomo C radiation therapy system, which is part of the CNNC-Array joint venture. The synergistic pairing of these two products is designed to facilitate highly precise radiotherapy treatments.
The TPS system, which is now approved for use in China, will enable physicians to create customized radiation therapy plans that are tailored to the Tomo C system’s helical imaging and radiation delivery capabilities. Manufactured locally through Accuray’s joint venture, this development is anticipated to broaden Accuray’s market penetration across China’s diverse regional markets.- Flcube.com
